Kinarus, a privately owned clinical-stage biopharmaceutical company active in the development of novel treatments for patients suffering from serious viral, respiratory and ophthalmic diseases, signed a Transaction Agreement with SIX-listed Perfect Holding regarding Perfect Holding's planned acquisition of Kinarus by way of a share exchange.
The closing of the transaction is subject to the fulfilment of specific conditions, including the approval by SIX Swiss Exchange of the listing of the new shares to be issued to the shareholders of Kinarus, and the approval of the envisaged transaction by the shareholders of both companies.
Schellenberg Wittmer advises Kinarus in this transaction. The team consists of Oliver Triebold, Marcel Jakob, Nicolas Kurz, Laura Roth, Irisi Arifi (all Corporate/M&A), Michael Nordin, Roland Wild (all Tax), Olivier Favre, Fabio Elsener, Dominic Wälchli, Daniel Reinger (all Banking & Finance), Lorenza Ferrari Hofer, Dimitry Bölsterli (IP/Life Sciences).
Copy linkLink copied
+41 44 215 5269
This site is protected by reCAPTCHA and the Google
Terms of Service apply.